 SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 GLOBE NEWSWIRE -- NGM Biopharmaceuticals, Inc. NGM Nasdaq: NGM, a biotechnology company focused on discovering and developing transformative therapeutics for patients, today disclosed its fourth oncology development candidate, NGM831, an antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well as with other ligands. The announcement coincides with a publication in Cancer Immunology Research, a journal of the American Association for Cancer Research,1 describing NGMs discovery of ILT3s functional ligand, fibronectin, an extracellular matrix protein that forms a fibrillar network within the tumor stroma. This discovery enabled the development of NGM831, which joins NGMs growing portfolio of wholly owned oncology antibody programs, including NGM120 anti-GFRAL, NGM707 anti-ILT2ILT4 and NGM438 anti-LAIR1. 